FIGURE 3.

(A) Immunohistochemistry (IHC) score could be used for MGMT status determination to predict overall survival (OS) in glioblastoma patients (area under the receiver operating characteristic curve [AUC] 0.656, brown line), but the efficiency was inferior to pyrosequencing (PSQ) (AUC: 0.709, red line). (B) Differences in IHC scores among PSQ‐defined hypermethylated, gray zone, and hypomethylated groups were significant (mean: 18.0%, 27.5%, and 49.7%, respectively; P < .001). (C, D) Patients with high MGMT expression (IHC score > 30%) showed inferior (C) progression‐free survival (PFS) and (D) overall survival (OS)